KURA
Kura Oncology·NASDAQ
--
--(--)
--
--(--)
4.61 / 10
Netural
Liquidity flow evaluation: 7.59/10 demonstrates robust fund flow characteristics. Optimistic Medium patterns are present, but pessimistic overall, block, Small, Large, and Extra-large indicators suggest a positive flow perspective. Analyst community shows an overwhelmingly bullish consensus with strong conviction, represented by 100% Strong Buy from one analyst, yet historical weighted rating of 1.62 implies limited reliability.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-13
InstitutionHC Wainwright & Co.
Times predicted6
Historical Win Rate16.7%
Is money flowing into or out of KURA?
- KURA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.61/10 (Netural).
